Literature DB >> 29194753

Immunogenicity of recombinant measles vaccine expressing fusion protein of respiratory syncytial virus in cynomolgus monkeys.

Akihito Sawada1, Kiyokazu Yunomae2, Tetsuo Nakayama1.   

Abstract

Respiratory syncytial virus (RSV) is a common cause of respiratory infections in infants. Effective vaccines are currently being sought, but no vaccine is thus far available. In our previous study, recombinant AIK-C measles vaccine expressing the RSV fusion protein (MVAIK/RSV/F) was developed and protective immunity against RSV demonstrated in cotton rats. In the present study, the immunogenicity and protective effects were investigated in three cynomolgus monkeys immunized with MVAIK/RSV/F. Neutralizing test antibodies against RSV were detected and no infectious virus was recovered from the lungs of monkeys immunized with MVAIK/RSV/F after challenge. MVAIK/RSV/F has the potential to inhibit RSV infection.
© 2018 The Societies and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  cynomolgus monkey; neutralizing antibody; recombinant measles vaccine; respiratory syncytial virus

Mesh:

Substances:

Year:  2018        PMID: 29194753     DOI: 10.1111/1348-0421.12559

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  2 in total

Review 1.  Engineering and combining oncolytic measles virus for cancer therapy.

Authors:  Mathias F Leber; Serge Neault; Elise Jirovec; Russell Barkley; Aida Said; John C Bell; Guy Ungerechts
Journal:  Cytokine Growth Factor Rev       Date:  2020-07-03       Impact factor: 7.638

Review 2.  Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines.

Authors:  Aileen Ebenig; Mona V Lange; Michael D Mühlebach
Journal:  NPJ Vaccines       Date:  2022-10-15       Impact factor: 9.399

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.